Vascular Biogenics analyst ratings
Vascular Biogenics analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/18/2022 | 161.59% | Oppenheimer | → $5.5 | Assumes | → Outperform |
| 04/28/2022 | 137.81% | Chardan Capital | → $5 | Initiates Coverage On | → Buy |
| 06/03/2021 | 232.94% | Roth Capital | $5 → $7 | Maintains | Buy |
| 01/28/2021 | 90.25% | HC Wainwright & Co. | $3 → $4 | Maintains | Buy |
| 04/17/2020 | 42.69% | Oppenheimer | $2 → $3 | Maintains | Outperform |
| 06/27/2019 | -4.88% | Oppenheimer | → $2 | Initiates Coverage On | → Outperform |
| 10/15/2018 | 42.69% | HC Wainwright & Co. | $3 → $3 | Upgrades | Neutral → Buy |
| 03/09/2018 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 03/08/2018 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 07/18/2022 | 161.59% | 奧本海默 | →$5.5 | 假設 | →跑贏大盤 |
| 04/28/2022 | 137.81% | 查爾丹資本 | →$5 | 開始承保 | →購買 |
| 06/03/2021 | 232.94% | 羅斯資本 | $5→$7 | 維護 | 買 |
| 2021年1月28日 | 90.25% | HC Wainwright公司 | $3→$4 | 維護 | 買 |
| 04/17/2020 | 42.69% | 奧本海默 | $2→$3 | 維護 | 跑贏大盤 |
| 2019年06月27日 | -4.88% | 奧本海默 | →$2 | 開始承保 | →跑贏大盤 |
| 2018年10月15日 | 42.69% | HC Wainwright公司 | $3→$3 | 升級 | 中性→購買 |
| 2018年03月09日 | - | 查爾丹資本 | 評級下調 | 購買→中性 | |
| 2018年03月08日 | - | HC Wainwright公司 | 評級下調 | 購買→中性 |
Vascular Biogenics Questions & Answers
血管生物遺傳學問答
The latest price target for Vascular Biogenics (NASDAQ: VBLT) was reported by Oppenheimer on July 18, 2022. The analyst firm set a price target for $5.50 expecting VBLT to rise to within 12 months (a possible 161.59% upside). 2 analyst firms have reported ratings in the last year.
奧本海默於2022年7月18日報道了血管生物製藥公司(納斯達克代碼：vblt)的最新目標價。這家分析公司將目標價定為5.5美元，預計VBLT將在12個月內升至(可能上漲161.59%)。去年有兩家分析公司公佈了評級。
The latest analyst rating for Vascular Biogenics (NASDAQ: VBLT) was provided by Oppenheimer, and Vascular Biogenics their outperform rating.
對血管生物製藥公司(納斯達克代碼：VBLT)的最新分析師評級是由奧本海默提供的，血管生物製藥公司的評級優於他們的評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vascular Biogenics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vascular Biogenics was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.
分析師在進行了廣泛的研究後，才得出股票評級，其中包括查閱公開財務報表，與血管生物基因公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。血管生物遺傳公司的上一次評級是在2022年7月18日提交的，所以你應該預計下一次評級將在2023年7月18日左右的某個時候公佈。
While ratings are subjective and will change, the latest Vascular Biogenics (VBLT) rating was a with a price target of $0.00 to $5.50. The current price Vascular Biogenics (VBLT) is trading at is $2.10, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的血管生物製藥(VBLT)評級為A，目標價在0.00美元至5.50美元之間。血管生物製藥(VBLT)目前的交易價格為2.10美元，在分析師的預測範圍內。